MyoKardia, Inc. (MYOK) Insider Joseph Lambing Sells 5,000 Shares
MyoKardia, Inc. (NASDAQ:MYOK) insider Joseph Lambing sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $40.00, for a total transaction of $200,000.00. Following the transaction, the insider now owns 104,718 shares in the company, valued at $4,188,720. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Joseph Lambing also recently made the following trade(s):
- On Tuesday, August 8th, Joseph Lambing sold 15,000 shares of MyoKardia stock. The shares were sold at an average price of $30.00, for a total transaction of $450,000.00.
Shares of MyoKardia, Inc. (NASDAQ MYOK) opened at 43.50 on Friday. The company’s market capitalization is $1.37 billion. The company has a 50-day moving average of $20.45 and a 200-day moving average of $14.89. MyoKardia, Inc. has a one year low of $10.55 and a one year high of $44.20.
MyoKardia (NASDAQ:MYOK) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.04. MyoKardia had a negative return on equity of 16.35% and a negative net margin of 44.65%. The company had revenue of $5.60 million for the quarter, compared to analyst estimates of $6.73 million. During the same quarter in the previous year, the business earned ($0.37) earnings per share. The company’s revenue was up 60.0% on a year-over-year basis. On average, analysts anticipate that MyoKardia, Inc. will post ($1.64) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “MyoKardia, Inc. (MYOK) Insider Joseph Lambing Sells 5,000 Shares” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/18/myokardia-inc-myok-insider-joseph-lambing-sells-5000-shares.html.
Several large investors have recently modified their holdings of MYOK. California State Teachers Retirement System raised its stake in shares of MyoKardia by 18.1% in the second quarter. California State Teachers Retirement System now owns 30,599 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 4,700 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of MyoKardia by 38.8% in the second quarter. The Manufacturers Life Insurance Company now owns 15,073 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 4,215 shares during the last quarter. State Street Corp raised its stake in shares of MyoKardia by 17.4% in the second quarter. State Street Corp now owns 232,581 shares of the biotechnology company’s stock valued at $3,048,000 after buying an additional 34,533 shares during the last quarter. Numeric Investors LLC acquired a new stake in shares of MyoKardia during the second quarter valued at about $254,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of MyoKardia during the second quarter valued at about $1,757,000. Institutional investors and hedge funds own 47.63% of the company’s stock.
Several equities analysts have recently commented on the stock. BMO Capital Markets restated a “buy” rating and set a $45.00 price target (up from $32.00) on shares of MyoKardia in a report on Tuesday, August 8th. Cowen and Company boosted their price target on shares of MyoKardia from $28.00 to $56.00 and gave the company an “outperform” rating in a report on Monday, August 7th. ValuEngine upgraded shares of MyoKardia from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Wells Fargo & Company restated an “outperform” rating and set a $48.00 price target (up from $31.00) on shares of MyoKardia in a report on Monday, August 7th. Finally, BidaskClub upgraded shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. MyoKardia has an average rating of “Buy” and an average price target of $37.60.
MyoKardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Stock Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related stocks with our FREE daily email newsletter.